Either you have JavaScript disabled or your browser does not support Javascript . To work properly, this page requires JavaScript to be enabled.
How to enable JavaScript in your browser?

A Phase 1, Randomized, Double-blind, Placebo-controlled, Multiple Ascending Dose Study to Evaluate the Safety and Tolerability of GX-I7 in HPV-infected Female Volunteers

Trial Profile

A Phase 1, Randomized, Double-blind, Placebo-controlled, Multiple Ascending Dose Study to Evaluate the Safety and Tolerability of GX-I7 in HPV-infected Female Volunteers

Completed
Phase of Trial: Phase I

Latest Information Update: 18 Dec 2018

At a glance

  • Drugs GX I7 (Primary)
  • Indications Human papillomavirus infections
  • Focus Adverse reactions
  • Sponsors Genexine
  • Most Recent Events

    • 21 Oct 2018 Status changed from recruiting to completed.
    • 01 Jun 2018 Planned End Date changed from 30 Mar 2018 to 30 Jun 2018.
    • 01 Jun 2018 Planned primary completion date changed from 15 Dec 2017 to 30 Jun 2018.
Restricted Access

Oops, it looks like you don’t have a valid subscription to this content. To gain full access to the content and functionality of the AdisInsight database try one of the following.

  • with a username/password associated to an account with a valid subscription
  • Contact your organization’s admin about adding this content to your AdisInsight subscription
  • Request a trial

If you are a subscriber to this content then contact us at AsktheExpert.AdisInsight@springer.com so we can help.

Back to top